Real-World Efficacy and Safety of Paclitaxel-Gemcitabine in Relapsed Small-Cell Lung Cancer
Authors:
- Edouard DantoingEDEdouard Dantoing
- Pierre DemontrondPDPierre Demontrond
- Bénédicte LéturgieBLBénédicte Léturgie
- Hubert CurcioHCHubert Curcio
- Charlotte OrsiniCOCharlotte Orsini
- Aude CoquardACAude Coquard
- Julie Tillon-StrozykJTJulie Tillon-Strozyk
- Radj GervaisRGRadj Gervais
- Luc ThibervilleLTLuc Thiberville
- Suzanna BotaSBSuzanna Bota
- Florian GuisierFGFlorian Guisier
Preprint
- 13 May 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Small-cell lung cancer (SCLC) is a cancer with poor prognosis. For relapsed extensive-stage (ES) SCLC, second-line treatment options are scarce. Topotecan was the only approved treatment in this setting until 2020. Since topotecan induces significant toxicities, alternative off-label regimens are being used. This study evaluated real-world efficacy and safety of Paclitaxel Gemcitabine chemotherapy in patients with relapsed ES-SCLC. We retrospectively reviewed data from all consecutive patients with relapsed ES-SCLC who received Paclitaxel Gemcitabine chemotherapy from september 2008 to january 2022 in two centers. Patient characteristics (n=188) were: PS≥2: 24.5%; brain metastasis: 42%; platinum-sensitive disease: 41%. Patients received Paclitaxel Gemcitabine as second- (77%) third (18%) or fourth (6%) line of therapy. Median progression-free and overall survival were 2.1 (95CI 1.8–2.4) and 3.8 (95CI 3.3–4.8) months in the overall population, respectively, with 17% response rate (RR) and 28% disease-control rate. PS, history of brain radiation, platinum-sensitive disease, liver, and adrenal gland metastasis were associated with longer survival in univariate analysis. PS was the only prognostic factor in multivariate analysis, with 21% RR and 4.1 months median DOR in PS 0-1 patients. Paclitaxel Gemcitabine chemotherapy may represent a treatment option in PS0-1 relapsed SCLC.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialThe Lancet Respiratory Medicine, 2022
- Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆Annals of Oncology, 2021
- Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialThe Lancet Oncology, 2020
- Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer expertsLung Cancer, 2020
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialThe Lancet Oncology, 2020
- Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortCancer Immunology, Immunotherapy, 2020
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histologyCancer, 2013
- Gemcitabine and Paclitaxel Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Phase II StudyClinical Lung Cancer, 2013
- Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trialCancer Chemotherapy and Pharmacology, 2005